Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Aravive Q3 EPS $(0.53) Up From $(0.66) YoY

Aravive (NASDAQ:ARAV) reported quarterly losses of $(0.53) per share. This is a 19.7 percent increase over losses of $(0.66) per share from the same period last year.

byBenzinga Newsdesk

October 28, 2021

1 minute read

Aravive (NASDAQ:ARAV) reported quarterly losses of $(0.53) per share. This is a 19.7 percent increase over losses of $(0.66) per share from the same period last year.

Deutsche Bank Maintains Hold on Nucor, Raises Price Target to $130

By vishwanath@benzinga.com

Today, 5:29 AM

Deutsche Bank analyst Chris Terry maintains Nucor (NYSE:NUE) with a Hold and raises the price target from $100 to $130.

NUE

MDC Partners With This Is Flow To Expand Global Footprint

By Shivani Kumaresan

Today, 5:29 AM

Advertising and marketing company MDC Partners Inc (NASDAQ:MDCA) has announced a partnership with This is Flow, an Australia-based media agency. The partnership will…

MDCA

Credit Suisse Maintains Outperform on IQVIA Holdings, Raises Price Target to $265

By Benzinga Newsdesk

Today, 5:29 AM

Credit Suisse analyst Erin Wilson maintains IQVIA Holdings (NYSE:IQV) with a Outperform and raises the price target from $242 to $265.

IQV

Vertex Pharma’s Stem Cell Derived Diabetes Treatment Trial Put On Hold

By Vandana Singh

Today, 5:29 AM

The FDA has instituted a clinical hold on Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) VX-880 Phase 1/2 study due to a determination that there…

VRTX

Aravive Q3 EPS $(0.53) Up From $(0.66) YoY

Related Posts

Deutsche Bank Maintains Hold on Nucor, Raises Price Target to $130

MDC Partners With This Is Flow To Expand Global Footprint

Credit Suisse Maintains Outperform on IQVIA Holdings, Raises Price Target to $265

Vertex Pharma’s Stem Cell Derived Diabetes Treatment Trial Put On Hold